SAT0601 Anti-il6-receptor tocilizumab in graves' orbitopathy. multicenter study of 29 patients. (12th June 2018)

• Record Type: Journal Article
• Authors: Atienza-Mateo, B.; Calvo-Río, V.; Martín-Varillas, J.L.; Demetrio-Pablo, R.; Valls-Pascual, E.; Valls-Espinosa, B.; Maiz-Alonso, O.; Blanco, A.; Torre, I.; Rodriguez-Mendez, V.; García-Aparicio, Á.; Veroz González, R.; Jovaní Casano, V.; Peiteado López, D.; Sanchez Orgaz, M.; Castañeda Sanz, S.; Tomero, E.; Toyos Sáenz, F.J.; Valvanera Pinillos, M.; Aurrecoechea, E.; Mora, Á.; González-Gay, M. Á.; Blanco, R.
• Is Part Of: Annals of the rheumatic diseases. Volume 77(2018)Supplement 2
• Page Start: 1153
• Page End: 1154
• Publication Date: 2018-06-12
• Subjects: Rheumatism -- Periodicals; 616.723005
• DOI: 10.1136/annrheumdis-2018-eular.4830
• Languages: English
• ISSNs: 0003-4967

Abstract

Abstract : Objectives: To assess the efficacy of Tocilizumab (TCZ) in refractory thyroid associated orbitopathy (TAO) due to Grave's disease. Methods: Multicenter study of 29 patients with TAO refractory to conventional immunosuppressive therapy. Results: We studied 29 patients (58 eyes) (23 women/6 men); mean age at diagnosis 48.79±12.39 years. Besides oral corticosteroids and before the onset of TCZ, patients had been treated with pulses of intravenous methylprednisolone (n=24), methotrexate (n=2) and other drugs (methimazole in 4 cases, leflunomide in 1, selenium in 9). Urgent decompressive surgery had to be performed in 2 patients. According to the classification of severity of the EUGOGO group (European Group on Graves' Orbitopathy) using the clinical activity score (CAS), before TCZ onset patients whose data were available had severe (n=14 eyes) or moderate (n=22 eyes) disease. Moreover, patients presented exophthalmos (n=30 eyes), strabismus (n=17 eyes), muscle fibrosis (n=15 eyes) and dysthyroid optic neuropathy (n=1). TCZ was used in monotherapy (n=27) or combined with methotrexate (n=2) at 8 mg/kg/iv/4 weeks (n=24) or 162 mg/sc/week (n=5). TCZ yielded rapid and maintained improvement in all ocular parameters (TABLE ). After a mean follow-up of 8.96±7.55 months using TCZ, all patients experienced ocular improvement, with TCZ withdrawal in 16 cases due to complete remission (n=5) or stability of ocular inflammation (n=11). Only 4 adverse effects were observed (neutropenia, external otitis, otitis media, costal osteitis). Conclusions: TCZ appears to be useful in TAO treatment. Reference: [1] Bartalena L, Baldeschi L, Dickinson AJ, et al. Consensus statement of the European group on Graves' orbitopathy (EUGOGO) on management of Graves' orbitopathy. Thyroid2008;18(3):333–346. Disclosure of Interest: None declared